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Abstract
The autonomic nervous control of cardiovascular (CV) system plays a major 
role in the adaptation of the organism to the changes in external and internal 
environment. It’s dysfunction is the major pathophysiological factor in the 
development of neurocardiovascular diseases. The aim of this review is to present 
the state of the art on the role of candidate gene polymorphisms of the molecules 
in the signaling chain of neurocardiovascular transmission in neurocardiovascular 
diseases. Neurocardiovascular disorders can be classified as sympathetic vs. vagally 
mediated disorders, though in many disorders both systems are dysfunctional. A 
number of molecules along the signaling pathway can be functionally modified and 
be the background of the predisposition, faster progression or complicated form of 
the disease. When the disease is the consequence of the joined parasympathetic 
and sympathetic nervous system disequilibrium, the focus of neurogenetic 
research should be on molecules providing the cross-talk between the two 
systems: on intercellular and intracellular level and on the level of the signaling 
process integration. An aggregation of positive results for the association between 
certain genes and different neurocardiovascular phenotypes pointed on a specific 
"neurocardiovascular genetic hotspots". Identification of these genes could be of 
particular interest as a diagnostic tool in the clustered form of neurocardiovascular 
diseases. New data obtained from neurogenetic approach will improve the disease 
outcome by gene, pharmacologic and behavioral modulation of the autonomic 
nervous system.
Keywords: Gene polymorphisms, Autonomic, Neurocardiovascular, Sympathetic, 
Parasympathetic, Therapy 
Abbreviations: AC-adenyl cyclase, ACE-angiotensin converting enzyme, ACE-
angiotensin-converting enzyme, Ach-acetylcholine, AchE-acetylcholine esterase, 
ADRA1A-alpha 1A adrenoceptor, ADRA1B-alpha 1B adrenoceptor, ADRA1D-
alpha 1D adrenoceptor, ADRA2A-alpha 2A adrenoceptor, ADRA2B-alpha 2B 
adrenoceptor, ADRA2C-alpha 2C adrenoceptor, ADRB1-beta 1 adrenoceptor, 
ADRB2-beta 2 adrenoceptor, ADRB3-beta 3 adrenoceptor
AF-atrial fibrillation, AGT-angiotensinogen, AGTR1-angiotensin receptor type 
1, ALDH-aldehyde dehydrogenase, ANS-autonomic nervous system, BH4-
tetrahydrobiopterine, Ca2+ ATPase-copper ATPase, CAD-coronary artery 
disease, cAMP-cyclic adenosine monophosphate, CASQ2-calcium sequestrin 2, 
CgA-catestatin- chromogranine A-catestatin, CholAT-choline acetyl transferase, 
COMT-catechol-O-methyl transferase, CPVT-catecholaminergic polymorphic 
ventricular tachycardia, CV-cardiovascular, DBH-dopamine-beta-hydroxylase, 
DHPG-dihydroxyphenylglicol, DHPR-dihydrobiopterine reductase, DOPA- 
dihydoxyphenylalanine, DRD1A-dopamine receptor type 1A, eNOS-endothelial 
nitric oxide synthase, FD-familial dysautonomia, GC-guanylil cyclase, GCH1-GTP 
cyclohydrolase, GNAS1-Gs protein alpha subunit, GNB3-G protein beta 3 subunit, 
KCNN3-potassium intermediate/small conductance calcium activated channel, 
subfamily N, member 3, KCNQ1-potassium voltage-gated channel, KQT-like
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Introduction
The adaptation of an organism to changes in external and internal 
environments is regulated by the autonomic nervous system [1-
4]. The neural control of cardiovascular (CV) system plays a major 
role in such adaptations, even if different humoral mechanisms 
also participate in this control. The fact that “cardiovascular 
diseases are the leading cause of death in the world today and will 
remain so by the year 2020” strongly supports the need for new 
insights into CV neural regulatory mechanisms [5]. Mechanisms 
of neural CV regulation can be studied on systemic level by using 
different techniques of monitoring CV variables [6-12]. On the 
other hand, a rapid advance is taking place in the field of the 
molecular genetics of autonomic disorders of CV system [6]. An 
integrative approach of these two fields promises new aspects 
on pathophysiological mechanisms of autonomic disorders of CV 
system.
CV autonomic disorders can be classified as specific syndromes, 
sympathetic versus vagally mediated disorders [13]. We adopted 
this classification for its simplicity and orientation towards 
causality of the disease.
1.Sympathetic disorders can be classified as 
a.Diseases in which activation of catecholamine system worsens 
an independent pathological state (coronary artery disease, 
arrhythmias (long QT syndrome, sudden death) and heart failure), 
and
b.Diseases in which abnormal catecholaminergic function is 
etiologic (sympathetic neurocirculatory failure, hypertension, 
cardiac necrosis and cardiomiopathy.
2.Vagally mediated cardiovascular diseases are
a.Neurally mediated syncope (vasovagal syncope, carotid sinus 
hypersensitivity)
b.Vagally mediated atrial fibrillation
Mechanisms of these diseases are complex and multisystemic, 
involving endocrine, metabolic and immune system having 
autonomic nervous system in a central place as the major 
coordinator of patophysiological process [14]. Autonomic nervous 
system, being an interface between external environment 
and internal milieu buffers external stressful influences and 
coordinates the above mentioned bodily systems in order to 
achieve new, adapted body equilibrium. This role is damaged in 
neurocardiovascular diseases and this damage is more clearly 
described on the systemic level [6] as the change in modulation 
and phase of sympathetic and parasympathetic branch. Not 
much is known about autonomic molecular mechanism of 
pathophysiological changes. This gap in knowledge is especially 
present in the light of the question why some patients are more 
and some less susceptible to these diseases. Neurotransmission 
is molecular process strongly dependent on genetic background 
which profiles the phenotype of autonomic nervous system, both 
it’s strong, protective and weak points. We applied the systematic 
candidate gene analysis of the molecular network participating 
in the neurotransmission of sympathetic and parasympathetic 
nervous system, while more detailed facts about these 
pathophysiological entities can be found in Golstein 2001 and 
Mathias & Bannister 2013.
This review focuses on the understanding of CV neurogenetics, in 
specific the genetic polymorphisms of the peripheral components 
of autonomic nervous system- sympathetic and parasympathetic 
signaling, metabolic pathways and molecular interactions. Their 
influence on regulatory mechanisms in autonomic disorders of 
CV system is of primary importance.
Sympathetically mediated cardiovascular 
disorders
1a. Candidate genes in sympathetic disorders in which activation 
of catecholamine system worsens an independent pathological 
state: Candidate genes for sympathetic disorders can be found 
all along the sympathetic signaling pathway (Figure 1) whose 
subfamily, member 1, LAAAD-L-aromatic amino acid decarboxylase, LQT1-long QT 
syndrome type 1, LQTS-acquired long QT syndrome, MAO-monoamine oxidase, 
MI-miocardial infarction, minK- subunit of IKS K+ channels, M-muscarinic receptor, 
NET-norepinephrine transporter, N-nicotinic receptor, NO-nitric oxide, NOS-nitric 
oxide synthase, PD-Parkinson disease, PKC-protein kinase C, PLCβ-protein lipase C 
beta, PNMT-phenylethanolamine-N-methyltransferase, POTS-postural tachycardia 
syndrome, RGS-cardiac regulator of G-protein signaling, RNLS-renalase, RRS-
ryanodine receptors on sarcoplasmatic reticulum, RyR2-ryanodyne receptor 2, 
SCD-sudden cardiac death, SC-stress cardiomyopathy
SERCA-sarcoplasmatic reticulum Ca2+ ATPase, SLC6A4-serotonin transporter, SNF-
sympathetic neurocirculatory failure, SNP-single nucleotide polymorphism, TH-
tyrosine hydroxylase, VACHT-vesicular acetylcholine transporter, VMAT2-vesicular 
monoamine transporter 2, VVS-vasovagal syncope, α-syn-alpha synuclein
ARCHIVES OF MEDICINE
2015
Vol. 7 No. 2:5
3 This article is available from: www.archivesofmedicine.com
milestones are genes of adrenergic receptors (alpha1A (ADRA1A), 
alpha1B (ADRA1B), alpha1D (ADRA1D), alpha2A (ADRA2A), 
alpha2B (ADRA2B), alpha2C (ADRA2C), beta1 (ADRB1), beta2 
(ADRB2), beta3 (ADRB3), dopamine receptor type 1A (DRD1A)), 
norepinephrine transporter (NET), G-proteins (Gs protein 
alpha subunit (GNAS1), G protein beta 3 subunit (GNB3). Other 
molecules, also a part of intracellular signaling pathways, like 
G protein related kinases (GRK 1-7) are interesting candidates 
for genetic evaluation, but are still on the very beginning of full 
elucidation of their role in neurocardiovascular diseases [6].
 Another functionally coupled network of molecules is responsible 
for the complex metabolic dynamics of catecholamines 
involving: synthesis (tyrosine hydroxylase (TH), enzymes of 
tetrahydrobiopterine metabolism (GTP cyclohydrolase GCH1, 
dihydrobiopteridine reductase DHPR), L-aromatic-amino-acid 
decarboxylase (LAAAD), dopamine-beta-hydroxilase (DBH), 
copper ATPase), inactivation (monoamine oxydase (MAO) , 
catechol-O-methyltransferase (COMT), phenylethanolamine 
N-methyltransferase (PNMT), aldehyde dehydrogenase (ALDH1A1 
and ALDH2)) and storage (vesicular monoamine transporter 2 
(VMT2), H+vesicular ATPase and chromograninA-catestatin (CgA) 
[13-15] (Figure 2). These molecules deserve special attention for 
candidate gene studies( Table 1).
Coronary artery disease
Coronary artery disease (CAD) is a multifactorial disorder 
which results from the interactions between the number of 
genetic and non-genetic factors [16,17]. It includes the group 
of pathophysiological conditions where coronary oxygen supply 
is decreased or blocked, generally due to atherosclerotic 
plaque. Sympathetic overactivity, an important component of 
these syndromes, can be boosted by environmental conditions 
(psychological stress [18, 19], smoking [20] which interact with 
the genetically determined response pattern. The research on the 
role of genetic polymorphisms of the molecules in the sympathetic 
signaling pathway was put on adrenergic receptors, identifying 
ADRA as the critical place of sympathetic cytophysiology in CAD. 
Gene polymorhisms of these receptors which are responsible 
for coronary vasoconstriction (Figure 1), are the risk factors for 
the genesis of CAD. Less net results are obtained for ADRBs, 
the important mediators of vascular dilatation (Figure 1). The 
divergent results could be interpreted to be the consequence 
of the studies on different populations, different syndromes and 
parameters of CAD, and different impact of gene-environment 
interaction. An interesting result is obtained by [21], reporting a 
protective role of C825T polymorphism of GNB3 subunit in CAD. 
The protective role of this polymorphism was present in the 
circumstance of the lifestyle change [21], becoming in this way an 
indicator for behavioural therapy, a useful marker of the patient 
prognostic outcome and a potential target for pharmacotherapy 
research. 
GCH1 is the rate limiting enzyme in the synthesis of 
tetrahydrobiopterine (BH4), an important cofactor for TH activity 
and NO dependent mechanism of acetylcholine vasodilatation 
[17], (Figure 3) The decreased rate of BH4 bioavailability may 
cause the dysfunction of both components of ANS (vagal and 
catecholaminergic) and join to this pathophysiological context 
an increased superoxide production, a known risk factor for 
atherosclerosis. The fact that 3 od 13 SNPs were found in promoter 
region of GCH1 speaks in favor that different polymorphisms 
might affect alternative tissues (vascular tissue vs. kidney) 
[22]. GCH1 genotypes might be useful in defining the specific 
phamacogenomic therapy in susceptible patients. Another gene 
relevant for BH4 bioavailability, DHPR, shows an association 
between its activity and acetylcholine induced vasodilatation, 
but till now no studies were performed on the association of 
DHPR SNPs and CAD [23]. The SNP of renalase, enzyme with 
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Figure 1. The sympathetic neuroeffector junction pre- and 
postsynaptic locations of proteins encoded by genes reviewed. 
The scheme illustrates the functions of neuronal ending of a 
postganglionic sympathetic axon innervating cardiomyocytes and 
vascular smooth muscle cells. 
Figure 2. The acetylcholinergic neuroeffector junction pre- and 
postsynaptic locations of proteins encoded by genes reviewed in 
this study. The scheme illustrates the functions of neuronal ending 
of an efferent acetylcholinergic axon innervating cardiomyocytes, 
vascular smooth muscle cells and postganglionic sympathetic 
neuronal cell. An illustration represents also an interaction between 
acetylcholinergic and noradrenergic neuronal ending, in specific 
the muscarinic heteroreceptor modulation of norepinephrine 
release.
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Genes 
important for 
catecholaminergic 
neurotransmission
Diseases in which activation of catecholamine system worsens an independent pathological state
CAD arrhythmias HF
ADRA1A
ADRA1B
ADRA1D
ADRA2A
ADRA2B
D/D (Snapir et al., 2001)
D/D(Snapir et al., 2003)
ADRA2C Del 322-325 (Park et al., 2006) Del 322-325#  (Shin et al., 2007)Del322-325# (Savva et al., 2009)
ADRB1
Ser49Ser (Hassan et al., 2008)
Gly389Arg#(Park et al., 2006)
Codons 49 and 389(Hassan et al., 2008)
Gly 389 Arg, Ser 49 Gly (Ulucan et al., 2008)
Ser49Gly, Arg389Gly#(Paavonen et al., 2007)
Ser49Gly,Gly389Arg # (Kanki et al., 2002)
Ser49Gly*(Borjesson et al., 2000)
Ser49Gly(Podlowski et al., 2000)
Arg389# (Tesson et al., 1999)
Arg389(Mialet Perez et al., 2003)
Gly49Gly (Pereira et al., 2012)
S49G, R389G#(Shin et al., 2007) 
ADRB2
46A(Zak et al., 2008)
Gln27(Park et al., 2006)
Arg16Gly#(Park et al., 2006)
Glu27*(Heckbert et al., 2003)
Codons 16,27 and nucleotide 523# 
(Hassan et al., 2008)
Arg16Gly, Gln27Glu,Thr16Ile (Ulucan et al., 
2008)
Thr184Ile#(Kanki et al., 2002)
Gln27Gln (Sotoodehnia et al., 2006)
Gly16Arg#(Sotoodehnia et al., 2006)
Thr164Ile (Brodde et al., 2001)
Glu27Glu, Arg16Arg (Pereira et al., 
2012)
Arg16Gln27 (Shin et al., 2007)
ADRB3
DRD1A
NET
GNAS1
GNB3
C825T ,1429G>A, IVS5+41G>A, 657T>A, 
814G>A# (Renner et al., 2007)
C825T* (Michalsen et al., 2006)
C825T(Wieneke et al., 2006)
T825T*(Schreieck et al., 2004)
GRK GRK5 Leu41* (Cresci et al., 2009)
Genes 
important for 
catecholaminergic 
metabolism
TH
GCH1 C+243T(Zhang et al., 2007)
DHPR
LAAAD
DBH
Cu2+ATPase
PNMT
MAO
rs2576178 A > G , rs2296545 C > G # 
(Fava et al., 2012)
rs2296545 C > G (Farzaneh-Far et al., 
2010)
rs2296545 C > G (Farzaneh-Far et al., 
2010)
COMT LL (Happonen et al., 2006)
ALDH
ALDH2rs671 (G>A) ((Han et al., 2013)
ALDH2rs671 (G>A) (Wang et al., 2013)
H+ vesicular ATPase
VMAT2
CgA-catestatine
* - protective effect
 # - no association was found.
Table 1. The association between candidate genes and neurocardiovascular diseases where the activation of catecholamine system worsens an 
independent pathological state
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MAO activity, was recently shown to be associated with inducible 
cardiac ischemia [24]. The study conducted on the enzyme of the 
adrenergic metabolism COMT showed that a heavy coffee intake 
increased the risk of CAD in patients with LL genotype pointing 
out on the importance of this gene-environment interaction [25].
ALDH (ALD1A1 and ALDH2) are the important enzymes in the 
mechanism of the toxic aldehyde clearance in the circumstances 
of acute myocardial ischemia and have protective effect for 
reperfusion arrhythmogenesis [26]. A recent meta-analysis [27,28] 
provide convincing data about the association of ALDH2 SNP 
rs671 (G>A) with the risk of CAD and MI. Compartmentalization 
of monoamines into vesicles is the dominant mechanism of 
monoamine removal from cytoplasm and prevention of their 
toxic effects [15]. Dynamic interaction between different protein 
components of these compartments is essential for monoamine 
metabolism. The most studied proteins are VMAT2, H+ATPase 
and CgA-catestatin. VMAT2, H+ATPase and CgA-catestatin SNPs 
role in the CAD development still is missing.
Arrhythmias
Different types of arrhythmias were investigated for the role of 
SNPs as their risk factors. Due to their role in the modulation 
of signal transduction and arrhythmogenesis ADRB receptors 
deserved most of the attention. Idiopathic ventricular arrhythmias 
commonly refer to ventricular tachycardia and/or frequent/
monomorphic premature ventricular contractions in patients 
with structurally normal heart [29]. Activation of sympathetic 
tone has been shown to play an important role in the provocation 
and maintenance of these arrhythmias.
Negative result for the participation of ADRB as the risk factor 
in the genesis of torsades de pointes was obtained by [30]. 
An interesting study was performed by Paavonen et al., who 
investigated the association between ADRB SNPs with ECG 
characteristics of the patients with long QT syndrome and the risk 
of SCD [31]. No association was found and possible explanation 
of this result was that stimulation of ADRB potentiates the risk of 
SCD by different mechanism. Ulucan et al., found that patients 
with idiopathic ventricular arrhythmias had higher frequency of 
Arg389Arg genotype, Arg389Gly49, and Arg389Ser49 haplotypes 
of the ADRB1, and higher frequency of Gly16Gly, Glu27Glu 
genotypes and Gly16Gln27Thr164, Gly16Glu27Thr164, and 
Gly16Glu27Ile164 haplotypes of the ADRB2 compared to control 
subjects [32]. Their results show that common SNPs in the ADRB1 
and ADRB2 are significantly associated with idiopathic ventricular 
arrhythmias in Turkish population. 
One potential genetic marker for sudden cardiac arrest is located 
in a gene coding the G-protein. The G-protein participates in 
intracellular signaling cascades relevant also for the regulation 
of ventricular rhythm. Moreover, some evidence has indicated 
that the G-protein might be directly involved in the genesis 
of atrial and ventricular arrhythmias [33,34]. Wieneke et al., 
studied whether the C825T polymorphism in GNB3 might serve 
as a genetic marker for recurrent ventricular arrhythmias [32]. 
Homozygous carriers of the C825 allele had a 3.9-fold risk for 
severe ventricular arrhythmias. An interesting result was obtained 
by Schreiech et al., who investigated a possible impact of the 
GNB3 C825T polymorphism on atrial fibrillation in an association 
study [35]. They concluded that there was an association between 
the GNB3 TT genotype and a reduced risk for the occurrence 
of atrial fibrillation. The fact that GNB3 C825T polymorphism 
plays the opposing roles in the genesis of ventricular vs. atrial 
arrhythmias is in line with the fact that these arrhythmias have 
different pathophysiological mechanisms, with different roles 
of sympathetic and vagal influence on their genesis. G proteins 
are an important component of the signaling pathway of both 
sympathetic and parasympathetic nervous system and integrative 
G protein functioning might be crucial for the resulting cellular 
response on sympatho-vagal drives. Again, the different results 
on the role of ADRB and G protein polymorphisms are obtained 
in different experimental designs and on different populations. A 
detailed investigation on the role in arrhythmogenesis of above 
reported and other molecules of the sympathetic signaling 
pathway is necessary.
Although a significant association between the expression of 
GCH1 and heart rate was confirmed, no study was done about 
the association between different GCH1 SNPs and arrhythmias 
[36]. Considering the proteins of monoamine vesicular 
compartmentalization, an initial research is done on the role of 
VMAT2 in arrhythmogenesis [37]. Further studies are needed on 
the role of vesicular proteins SNPs in arrhythmias. 
Heart failure
One of the main functions of the cardiac adrenergic system is to 
regulate cardiac work both in physiologic and pathologic states. A 
better understanding of this system has permitted the elucidation 
of its role in the development and progression of heart failure 
(HF). Enhanced sympathetic activation has a central role in the 
development and progression of HF [38]. 
Liggett et al., have demonstrated that adrenergic polymorphisms 
affect not only receptor signaling and sensitivity to pharmacological 
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agents, but also influence clinical outcomes of HF; for ADRB1, 
two polymorphic loci have been investigated: Ser49Gly and 
Arg389Gly polymorphism [39,40]. Borjessen et al., also found 
that allelic distribution of Ser49Gly has been associated with long 
term survivor in patients with HF [41]. This is consistent with idea 
that downregulation and desensitization of ADRB1 receptors is 
protective in HF [42]. On the contrary, Podlowski et al., found 
that Ser49Gly is more frequent in patients with idiopathic dilated 
cardiomyopathy [43]. Another important ADRB1 polymorphism is 
a Arg389Gly polymorphism in the fourth intracellular loop, which 
participates in G protein coupling. The polymorphism Arg389 of 
Arg389Gly, is threefold more effective than is the Gly389 variant 
at activating adenylyl cyclase [44], which speak for the higher 
potential of Arg389 carriers in initiation and maintenance of 
cardiac hypertrophy. Still, no correlation between Arg389 and HF 
was observed by Tesson et al., [45], but more recent results of 
Mialet Perez et al., [46] show that when expressed Arg389, even 
at low level, in mouse hearts induces HF. More, the responses to 
antagonists are more pronounced in Arg389 than in Gly389. It is 
of interest that Arg389 significantly increases the cardiovascular 
risk of HF in subjects with ADRA2C deletion variant [47]. 
These data suggest the importance of interaction of individual 
polymorphisms in the development of pathological state.
ADRB2 are highly polymorphic. One rare variant, Thr164Ile 
is associated with reduced survival and depressed exercise 
capacity in HF patients [48]. In the study of Pereira et al., ADRB1 
polymorphisms (Ser49Gly, Arg389Gly and Gln27Glu) and ADRB2 
polymorphisms (Gln27Glu and Arg16Gly) were investigated for 
the association with HF progression, drug response and clinical 
outcome [49]. Genotypes Gly49Gly of the ADRB1 polymorphism 
and Glu27Glu and Arg16Arg of ADRB2 polymorphisms were 
higher in HF patients compared with healthy population. Their 
study showed the racial specificity where black population with 
Ser49Ser genotype showed a reduced survival rate with respect 
to other two genotypes of ADRB1.
The role of adrenergic receptors genetic polymorphisms in adverse 
events of the HF, defined as death or heart transplantation were 
investigated in the study of Shin et al., [50]. Eight polymorphisms 
in 6 genes were genotyped: ADRB1 (S49G, R389G), ADRB2 (G16R, 
Q27E), ADRA2C (insertion/deletion 322-325), angiotensinogen 
(AGT, M235T), angiotensin receptor type 1 (AGTR1, 1166A>C), and 
angiotensin-converting enzyme (ACE, insertion/deletion in intron 
16). On the basis of this investigation, only ADRB2 Arg16Gln27 
haplotype may significantly increase the risk of adverse outcomes 
in patients with HF receiving contemporary HF pharmacotherapy. 
Savva et al., investigated whether the ADRA2C (Del322-325) 
polymorphism exclusively or in combination with a ADRB1 
(Arg389) polymorphism, each with known independent effects 
on sympathetic function, were associated with an increased risk 
of adverse events in HF [51]. The authors have found that the 
ADRA2C Del322-325 polymorphism exclusively or in combination 
with the ADRB1 Arg389 allele is not associated with an increased 
risk of adverse events in HF. 
The contribution of adrenergic receptors to the development of 
HF needs to be more thoroughly investigated: studies designed to 
consider many complex haplotypes including the combination of 
individual polymorphisms are necessary.
Functionally significant gene variants of the G-protein receptor 
kinases (GRKs) that phosphorylate and uncouple ADRB receptors 
from their downstream signaling effectors were candidates 
for polymorphism studies. One common nonsynonymous 
polymorphism was found, substituting Leu for Gln at GRK5 amino 
acid 41 [52]. This polymorphism is rare in individuals of European 
descent, but approximately 40% of individuals of African ancestry 
are the carriers. This polymorphism increases ADRB1 and ADRB2 
desensitization [52,53]. The first clinical study of the GRK5 Leu41 
polymorphism showed that beta-blocker naive carriers had 
improved transplant-free survival [54]. The GRK5 interaction 
with HF has only been described in the absence of beta-blocker 
therapy, which is the standard of care for essentially all forms of 
HF [55].
Considering the association studies of SNPs important for the 
catecholamine metabolism and HF, the noticeable lack of data 
is present. The SNP of renalase, enzyme with MAO activity, was 
recently shown to be associated with clinical parameters of HF 
[24].
1b. Candidate genes in sympathetic disorders in which abnormal 
catecholaminergic function is etiologic (Table 2).
Sympathetic neurocirculatory failure
Sympathetic neurocirculatory failure (SNF) features orthostatic 
hypotension and abnormal beat-to-beat blood pressure 
responses to the Valsalva maneuver. This pathophysiological 
phenomenon is present in Pure autonomic failure (or Bradbury-
Eggleston syndrome or idiopathic orthostatic hypotension), Shy-
Drager Syndrome (multiple system atrophy with sympathetic 
neurocirculatory failure) and Parkinsonism with peripheral 
autonomic failure [13].
Several features of idiopathic orthostatic hypotension have been 
attributed to hypoactive or hyperactive states of adrenergic 
receptors of the sympathetic nervous system. Focused on this 
fact, Winker et al., wanted to ascertain whether genotypes at 
eight polymorphic loci within five relevant adrenergic receptor 
genes (ADRA2A, ADRA2B, ADRA2C, ADRB1 and ADRB2) influence 
the risk for idiopathic orthostatic intolerance [56]. They found 
for the ADRB1 Gly49 polymorphism a decrease in the risk of 
idiopathic orthostatic intolerance among persons who were 
homozygous, implying its protective role. No other associations 
for other adrenergic receptors polymorphisms and idiopathic 
orthostatic intolerance were found.
The norepinephrine-synthesizing DBH is a reasonable candidate 
gene for autonomic diseases with sympathetic insufficiency [57]. 
On the basis of their previous findings, the authors hypothesized 
that mutations found on DBH locus might be risk factors for 
autonomic diseases like orthostatic intolerance, pure autonomic 
failure and multiple system atrophy. Three missense mutations 
(V87M, D100E, and D331N) were taken in consideration, but 
none of these mutations was revealed in reported autonomic 
syndromes. Even though the authors report the preliminary 
results, it is noteworthy that the frequency of the T allele 
mutation 1021C→T in orthostatic intolerance patients is slightly 
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Genes important for 
catecholaminergic 
neurotransmission
Diseases in which abnormal catecholaminergic function is etiologic
SNF Hypertension Cardiac necrosis and cardiomyopathy
ADRA1A
Cys/Cys #(Xie et al., 1999)
Cys/Cys (Freitas et al., 2008)
Cys/Cys *(Gu et al., 2006)
ADRA1B
Gly 
49*(Winker et 
al., 2005)
ADRA1D
ADRA2A
ADRA2B
ADRA2C
Del322-325* (Regitz-Zagrosek et al., 2006)
Del 322-325# (Sharkey et al., 2009)
ADRB1
Ser49Gly (Filigheddu et al., 2011)
Arg389Gly# (Filigheddu et al., 2011)
Ser49Gly*, Arg389Gly* (Forleo et al., 2004)
rs35230616#, rs1801253#  (Spinelli et al., 2010)
Ser49Gly#, Arg389Gly# (Sharkey et al., 2009)
Arg389Gly (Vriz et al., 2011)
rs1801253# (Figtree et al., 2013)
ADRB2
Arg16Gly (Kotanko et al., 1997)
Arg16Gly , Gln27Glu (Bray et al., 2000)
Arg16Gly (Busjahn et al., 2000)
Arg16Gly (Hoit et al., 2000)
Arg16Gly (Wu et al., 2006)
Arg16Gly#(Wu et al., 2006)
Cys19Arg# (Filigheddu et al., 2011)
Gly16Arg# (Filigheddu et al., 2011)
Gln27Glu# (Filigheddu et al., 2011)
5' LC Arg19Cys*, Arg16Gly*, Gln27Glu*, and 
Thr164Ile# (Forleo et al., 2004)
rs1042713#, rs1042714#, and rs1800888#  
(Spinelli et al., 2010)
Gln27Glu (Vriz et al., 2011)
rs1800888# (Figtree et al., 2013)
ADRB3 Arg64Trp#  (Forleo et al., 2004)
DRD1A
NET
rs168924 (Ono et al., 2003)
rs168924# (Zolk et al., 2012)
GNAS1 Fokl(+/-) (Jia et al., 1999) rs11554276#  (Spinelli et al., 2010)
GNB3
C825T (Beige et al., 1999)
C825T, C1429T(Cabadak et al., 2011)
G5177A#  (Cabadak et al., 2011)
C825T  (Niu et al., 2011)
A3882C#, G5249A# and C825T# (Filigheddu et al., 2011)
GRK
GRK5 rs17098707, rs34679178 (Spinelli et al., 
2010)
GRK5 rs17098707# (Figtree et al., 2013)
Genes important for 
catecholaminergic 
metabolism
TH C-824T (Nielsen et al., 2010)
GCH1 C+243T (Zhang et al., 2007)
DHPR
LAAAD
DBH
V87M, D100E, 
and D331N# 
(Cho et al., 
2003)
-1021C/T (Abe et al., 2005)
C-970T (Chen et al., 2010)
C-2073T (Chen et al., 2011)
Cu2+ATPase
PNMT PNMT-148, PNMT-353 (Cui et al., 2003)
G-367A, G-161A* (Huang et al., 2011)
MAO
rs2296545 (Buraczynska et al., 2011)
rs2576178# (Buraczynska et al., 2011)
rs2576178, rs10887800 (Stec et al., 2012)
rs2576178 A > G, rs2296545 C > G# (Fava et al., 2012)
Table 2. The association between candidate genes and neurocardiovascular diseases where abnormal catecholaminergic function is etiologic
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higher than that in controls. Some reasons for the lack of data on 
association studies between SNPs of catecholaminergic signaling 
and metabolic pathways and SNF, is due to the rarity of the 
syndrome and complexity of the clinical phenotype. 
Hypertension
Essential hypertension is a multifactorial disease with increasing 
number of evidence that increased and adverse activation of 
sympathetic nervous disease plays a crucial role in it's genesis 
[14,38]. Hypertension candidate genes act through all the signaling 
and metabolic pathways of catecholaminergic function [58]. In an 
effort to localize blood pressure influencing genes, Krushkal et al., 
[59,60] identified the long arm of human chromosome 5 (5q33.3 
to 34) as the region putatively containing ADRA1B, ADRB2 and 
DRD1A genes influencing systolic blood pressure levels in young 
Caucasians. Both ADRA1B and DRD1A genes are located close 
to these markers, suggesting that genetic variation in one or 
both of these receptors plays an important role in determining 
interindividual variation in systolic blood pressure levels. The 
same group [61] reported further data on association between 
the polymorphisms within the ADRB2 gene and systolic blood 
pressure among discordant siblings. Multiple lines of investigation 
indicate that the Arg16Gly and Gln27Glu polymorphisms in the 
ADRB2 gene significantly influence interindividual blood pressure 
variation and the occurrence of hypertension. Associations 
were detected between this polymorphisms and blood pressure 
in normotensive twins [62]. Studies by Hoit et al., add more 
evidence that the Gly16 variant imparts attenuated vasodilatory 
responses to catecholamines in humans, further emphasizing the 
ADRB2 gene role in the regulation of the arterial blood pressure 
[63]. There are also confirmed significant associations of essential 
hypertension in Yi minority group with separate SNPs of ADRB2 
[64]. In contrast no association was found in the Hani minority 
group. These data confirmed that the mutations of this gene show 
ethnic, as well as population and even subpopulation specificity.
The association of ADRA1A polymorphisms with blood pressure 
phenotypes was studied in different populations: Brasilian [65], 
African American and Caucasian population [66]. These studies 
revealed controversial role of ADRA1A in association to essential 
hypertension: presence of Cys/Cys genotype was associated with 
hypertension only in individuals with regular physical activity, 
while an initial report of Xie et al., found no association between 
this polymorphism and hypertension [66]. Recent studies 
showed that the Cys allele was associated with relatively lower 
hypertension prevalence in a Chinese population [67]. Again, 
these results suggested that genetic variations in ADRA1A could 
modulate cardiac or vascular sympathetic modulation in highly 
population dependent manner.
The attempts have been made to investigate the implication of 
NET in hypertension pathophysiology. The proposed hypothesis 
was that reduced uptake of norepinephrine could provide an 
increased concentration of catecholamines in neuromuscular 
synaptic cleft and circulation that would initiate and maintain an 
increased vasoconstrictor response of vascular smooth muscle 
cells. Still, both experimental [68,69]) and clinical findings 
[70] about the role of NET in hypertension remain without 
straightforward conclusion. NET gene (SLC6A2) is located and 
mapped [71], and its active role in hypertension is confirmed 
(NET gene silencing, [72]. Numerous SNPs have been identified, 
but only rs168924 is associated with essential hypertension in 
Japanese population [73]. A detailed analysis of the interrelation 
of rs168924 polymorphisms of NET gene and blood pressure 
parameters in Caucasian population provided opposite results- 
rs168924 G variant was associated with a lower prevalence of 
arterial hypertension [74]. There is also the possibility that some 
rare forms of hypertension, like hypernoradrenergic hypertension, 
could result from the genetic dysfunction of NET [75].
Several studies have reported the association of G protein 
polymorphisms and essential hypertension in some population, 
although contradictory results were reported. The study of 
Jia et al., demonstrates an association between a Fokl(+/-) 
polymorphism in the GNAS1 locus and hypertension [76]. More, 
the Fokl allele was more common in good responders than poor 
responders to blood pressure responses after beta-blocade. In 
the study of Cabadak et al., it was investigated the potential role 
of the C825T, C1429T, and G5177A polymorphisms of the GNB3 
in essential hypertension in a group of Turkish subjects [77]. 
The frequencies of the 825T and 1429T variants were higher in 
hypertensive subjects compared to those of controls.
Metaanalysis of alpha-adducin G460T and GNB3 C825T 
polymorphisms in southern Chinese population showed null 
association with hypertension but indicate local marginal 
significance of C825T, as a putative salt-sensitive switch [78]. 
By analyzing polymorphisms of ADRB1, ADRB2 and GNB3 
subunit, no single nucleotide polymorphisms or haplotypes were 
associated with essential hypertension in the study of Filigheddu 
F et al., [79]. In the same study in females only, GNB3 SNPs and 
haplotypes were associated with the blood pressure response to 
beta blockers. On the other hand, in the study of Beige et al., [80] 
the 825T allele of this polymorphism was associated with 50% 
increased chance of having hypertension compared with non-T 
carriers.
COMT
-1187G>C(Kamide et al., 2007)
rs4680 (Hagen et al., 2007)
rs4680 (Annerbrink et al., 2008)
rs4680 (Htun et al., 2011)
rs4680# (Figtree et al., 2013)
ALDH ALDH2 rs671# (Sen Zhang et al., 2013)
H+ vesicular ATPase
VMAT2
CgA-catestatine
* - protective effect
# - no association was found
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An increase of plasma catecholamines that accompanies the 
essential hypertension suggests catecholamine synthetic enzymes 
as hypertension candidate genes. The locus for TH, the rate limiting 
enzyme in the biosynthesis of catecholamines, was found to be 
associated with essential hypertension in case-control study [81]. 
The group of Nielsen et al., investigated the relationship between 
a common SNP in the proximal TH promoter (C-824T) and blood 
pressure in a large general population sample, characterized by 
24-h ambulatory blood pressure monitoring and office blood 
pressure measurement [82]. They reported that the C-824T 
SNP in the proximal TH promoter influences blood pressure and 
prevalence of hypertension in the general population.
GTP cyclohydrolase (GCH1) as a rate limiting enzyme of BH4 
biosynthesis, is a cross-talk component for cateholamine and 
NO synthesis, both being crucial components of hypertension 
pathophysiology. Zhang et al., confirmed that the SNP C+243T 
affected both diasolic and systolic blood pressure, principally in 
females providing an important clue that both traits (NO secretion 
and autonomic activity) are jointly genetically determined, and 
that this fact can have important impact on future diagnosis, 
prognosis and treatment of hypertension [22]. These results, 
obtained on Caucasian population, remain to be confirmed on 
other populations. 
Elevated levels of DBH, an important enzyme of catecholamine 
synthesis, are found in patients with essential hypertension. A 
novel polymorphism -1021C/T was found to interact with fasting 
plasma glucose level in association with hypertension, pointing 
on important gene-environment interaction in the genesis of 
hypertension obtained on Japanese population [83]. Another 
polymorphism of DBH C-970T was found to be associated with 
essential hypertension. These polymorphisms confers a wide 
range of autonomical traits: DBH expression and catecholamine 
secretion, heritable environmental stress-induced blood pressure 
increments, and ultimately – the risk for hypertension. Special 
attention deserves the observation that the C allele promoter 
variant, the most common variants in each population studied, 
is in line with “common disease/common allele” hypothesis 
for frequent pathophysiological traits that is certainly the case 
of essential hypertension. These findings are completed by 
the results on DBH polymorphism C-2073T on transcriptional 
and biochemical changes including augmented DBH secretion, 
eventuating in elevation of basal blood pressure, and hence 
cardiovascular risk [84]. This group in systematic and integrative 
approach revealed the role of DBH polymorphisms in the genesis 
of essential hypertension.
Methods in comparative genomics identified a genetic locus 
associated with blood pressure regulation in the stroke prone 
spontaneously hypertensive rats in a conserved synthetic 
group, corresponding to the gene for PNMT in humans [85]. A 
case/control association study was conducted to evaluate the 
relationship between genetic variants of the PNMT gene and risk 
for essential hypertension [86]. Two SNPs in the promoter region 
of the gene were genotyped, PNMT-148 and PNMT-353, in three 
ethnic samples: African American, American white, and Greek 
white population. A significant difference in allelic frequency of 
SNP-353 between hypertensives (38.02%) and normotensives 
(27.35%) in African Americans (P =.019) was found; however, no 
significant differences were observed for this SNP for the other 
ethnic groups. No association was found with SNP PNMT-148 
in any of the ethnic groups. These results suggest that genetic 
variants of PNMT may play a role in the development of essential 
hypertension in some populations. The population dependent 
role of PNMT polymorphisms in the genesis of hypertension was 
confirmed by Huang et al., [87] who found a protective effect 
of G-367A and G-161A 2-SNPs AA haplotype in Han Chinese 
population.
Renalase (gene name RNLS), an enzyme with monoamine oxidase 
activity, is implicated in the degradation of catecholamines 
(Figure 3). Two SNPs rs2576178 A > G and rs2296545 C > G 
were investigated for the association with hypertension and no 
association was found [88]. On the other hand, Buraczynska et 
al., found the association between rs2296545 and hypertension 
in patients with type 2 diabetes, as though the association was 
found between rs2576178 and rs10887800 and hypertension 
in renal failure patients [89,90]. The role of this enzyme in the 
hypertension genesis might be syndrome dependent.
COMT is an important enzyme of norepinephrine and estrogene 
metabolism and plays an important role in the regulation of 
norepinephrine plasma levels. COMT SNP -1187G>C was found to 
be associated with essential hypertension in Japanese men [91], 
while rs4680 was found to be associated with hypertension in 
Norwegian hypertension patients [92] and Sweedish men [93]. 
This result for rs4680 was confirmed by Htun et al., in Japanese 
men, with strong impact of an environmental factor-energy 
intake-on this interaction [94]. 
ALDH plays an important role in the interplay of catecholamine 
and alcohol metabolism. The association of this genotype with 
blood pressure was investigated in Chinese older men [95]. The 
association was found for alcohol dehydrogenase polymorphism 
but not for ALDH polymorphisms. This result speaks for the role 
of ethanol in the genesis of alcohol-associated hypertension, less 
for the role of aldehyde.
Even though there are novel data on the intravesicular interaction 
between H+ vesicular proton pump, CgA-catestatin system, 
catecholamine release and hypertension risk (in vitro, [96], no 
association study was done on the effect of SNPs of the vesicular 
proteins with hypertension.
In conclusion, it is worth to emphasize that hypertension, as the 
multifactorial multigenic disease, is strongly dependent on the 
cardiovascular reactivity to stress which is genetically determined 
and regulated by autonomic nervous system [97]. It is obvious that 
this gene-environment interactions are population dependent 
and that the molecular patterns of the cardiovascular reactivity 
to stress could also be population dependent. Still, this massively 
present disease in the developed countries speaks for the impact 
of environmental factor (stress) through different molecular 
“entrance gates” initiating the pathophysiological process that 
ends with common final phenotype- essential hypertension. This 
complex gene-environment interaction has to be addressed by 
systematic experimental approach combining gene, in vitro and 
in vivo studies of cardiovascular autonomic traits in different 
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populations [22].
Cardiac necrosis and cardiomyopathy
Stress cardiomyopathy (SC) (tako-tsubo, left ventricular apical 
ballooning syndrome) is a newly reported condition afflicting 
older women, characterized by acute left ventricular systolic 
dysfunction, triggered by emotionally and physically stressful 
events, and occurring without significant coronary obstruction. 
Sympathetic nervous system hyperactivity has been implicated in 
the pathophysiology of SC[13]. Other forms of cardiomyopathy, 
like idiopathic dilatatory cardiomyopathy are also closely related 
to sympathetic overactivity [98].
SNPs involving the ADRB1 (amino acid positions 389 and 49) and 
ADRA2C (deletion 322-325) were investigated for susceptibility to 
SC [99]. Genotype polymorphism frequencies for these receptors 
were not significantly different in SC patients compared to female 
controls. These data suggest that these adrenergic polymorphisms 
do not mediate the sympathetic nervous system hyperactivity in 
SC patients. Pre-synaptic ADRA2 are essential feedback regulators 
to control the release of norepinephrine from sympathetic 
nerves. In the study of Regitz-Zagrosek et al., they tested 
whether a deletion polymorphism in the human ADRA2C gene 
(Del322-325) affects progression of HF in patients with dilated 
cardiomyopathy [100]. The results have shown that ADRA2C Del 
may be a novel, strong, and independent predictor of reduced 
event rates like death and implantation of a left ventricular assist 
device in dilated cardiomiopathy patients. The same type of 
cardiomyopathy was investigated for the effects of ADRB variants 
for Ser49Gly and Arg389Gly in the ADRB1; the 5' LC Arg19Cys, 
Arg16Gly, Gln27Glu, and Thr164Ile in the ADRB2; and Arg64Trp 
in the ADRB3 [101]. The Gly49 allele in the ADRB1 and the 5' LC-
Cys19, Arg16, and Gln27 alleles in the ADRB2 were associated 
with a lower risk of HF in idiopathic dilated cardiomyopathy, 
suggesting that the ADRB1 and ADRB2 genes are modifier genes. 
Spinelli et al., postulated that polymorphisms associated with 
different ADRB responsiveness might play a role in the risk of SC, 
thus allowing the identification of those patients that are prone 
to SC after an adrenergic surge [102]. These authors confirmed 
the association of GRK5 L41polymorphism with SC, while the 
association for ADRB1, ADRB2 and GNAS1 were not found. This 
finding is consistent with the fact that GRK5 L41 polymorphism 
enhances desensitization and impairs ADRB response, reducing in 
this way the inotropic effect of catecholamines and compromising 
coronary blood flow [102]. On the other hand, the role of ADRB1 
and ADRB2 in the genesis of SC was confirmed by Vriz et al., [103]. 
In one of the largest cohorts of SC in the world, Figtree et al., on 
the other hand found no association between ADRB1, ADRB2, 
GRK5 and COMT polymorphism and SC. Inhomogeneous results 
are possibly due to the racial, ethnic and sample size differences 
[104]. Also, different gene-environmental interactions can play an 
important role for the diversity of the obtained results. 
There are several other neurocardiologic disorders where an 
abnormal catecholaminergic function is etiologic. For their role in 
the understanding of autonomic nervous system pathophysiology, 
special emphasis is drawn on:
a.Familial dysautonomia
b.Parkinson disease
cBaroreflex failure
d.Postural tachycardia syndrome
e.Catecholaminergic polymorphic ventricular tachycardia [13]
a.Familial dysautonomia (FD, Riley-Day syndrome), is one of 
several forms of hereditary sensory and autonomic neuropathies. 
This syndrome generally results from derangements in 
maturation and migration of neural crest-derived progenitor 
cells in the formation of sensory and autonomic population. 
The disease is transmitted as autonomic recessive trait, with the 
locus of genetic mutation on chromosome 9q31 which causes 
the deficiency of IKAP protein [105]. FD produces complex 
symptomatology, suggesting deficient activities of multiple 
neurotransmitter systems, catecholaminergic system being one 
of them. Elevated level of L-DOPA:DHPG ratio in patients [106] 
reflects decreased ability to synthesize NE and increased TH 
activity and depleted vesicular NE stores. This neurochemical 
pattern does not correspond to any single abnormality of 
catecholamine synthesis, signaling or metabolism, but suggest 
global arrested differentiation of catecholamine systems [13], 
mechanisms of which remain poorly understood.
Parkinson disease (PD) is often accompanied with cardiovascular 
dysautonomia. Catecholamine profile corresponds to decreased 
or absent synthesis, neuronal uptake and turnover. The findings 
are consistent with the loss of cardiac, extra cardiac sympathetic 
nerve terminals and baroreflex failure that progresses with time 
[107]. These results point on PD as not only central but also 
peripheral catecholaminergic neurodegeneration [13], where 
elucidation of cardiovascular dysautonomia could be the key point 
in understanding the pathogenesis of PD. An important point in 
understanding neurotoxicity in PD is the decrease of vesicular 
uptake: impaired vesicular sequestration builds up cytosolic 
catecholamines, which are toxic, by spontaneous auto-oxidation 
to quinines, enzymatic conversion to catecholaldehydes and by 
cytosolic catecholamine interactions with calcium and alpha-
synuclein (Figure 3). Still, no association was found in the study of 
VMAT2 polymorphism with PD in Japanese patients [108], as well 
as for the molecules participating in phosphorilation of alpha-
synuclein [109]. SNPs of other molecules in the catecholaminergic 
signaling and metabolic pathways play a significant role in the 
pathogenesis of PD, but the systematic review of this subject is 
out of scope of this review and can be found elsewhere [110].
c.Baroreflex failure is the syndrome usually with underlying 
organic pathology (familial paraganglioma syndrome, history of 
neck irradiation, surgical section of glossopharingeal nerve or 
NTS lesion) or with idiopathic etiology [13]. It is characterized 
by decreased/absent bradicardia responses to phenylephrine, 
decreased/absent tachycardia responses to nitroprusside, labile 
hypertension and orthostasis- or emotion-evocable episodes 
of marked increase in plasma catecholamine levels and blood 
pressure. The studies of individual/group genetic polymorphisms 
of catecholaminergic signaling and metabolic pathways in 
baroreflex failure are still lacking.
d.Postural orthostatic tachycardia syndrome (POTS) is 
characterized by a sustained increase in heart rate (30-120bpm) 
within 10min of orthostasis or head up tilt in the absence 
of orthostatic hypotension [111]. POTS include also exercise 
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intolerance, fatigue, chest pain and dizziness. It is considered as 
“partial dysautonomia”, manifesting incomplete, mild autonomic 
dysfunction that compensatorily activates sympathetic drives to 
other regions via baroreflex mechanisms. Nickander et al., [112] 
found no association between SNPs of ADRB2, ADRA2C, NET and 
mitochondrial complex I. Even though there was not confirmed 
the strong association between DBH genotype and POTS, Garland 
et al., suggest that differences in DBH activity in POTS patients 
might reflect the different levels of sympathetic activation [113]. 
In children with POTS of Japanese ethnicity an association was 
found with GNB3 polymorphism while the GNAS1 polymorhism 
was not associated with the syndrome [114]. Different results on 
the role of genetic polymorphisms of catecholaminergic signaling 
and metabolism might be the consequence of different sample 
size, age and ethnicity. More, the data on the influence of other 
SNPs of genes of catecholaminergic molecular machinery are 
lacking.
e.Catecholaminergic polymorphic ventricular tachycardia (CPVT) 
is an ion channelopathy of genetic origin (mutation of cardiac 
RyR2 and CASQ2 gene, Figure 1) characterized by life threatening 
ventricular arrhythmias triggered by sympathetic activity 
(physical activity or emotional stress) [115]. The identification 
of genes underlying stress-induced life-threatening arrhythmias 
in intact heart revealed that different arrhythmias are the 
same disease with different phenotype expression, all of them 
potentially leading to the clinical entity-SCD. RyR2 and CASQ2 
are molecules on the crossroad between the mechanisms of 
cardiac electrical and mechanical activation, having in this way 
an important role in the genesis of cardiomyopathy, another 
catecholamine associated disease [13]. The systematic analysis of 
the phenotypes with enhanced adrenergic response to physical 
or emotional stress in patients with calcium channelopathies is 
still lacking.
Vagally mediated cardiovascular diseases
Candidate genes for vagally mediated cardiovascular diseases 
are, as the ones for sympathetically mediated disorders, all along 
the vagal signaling and metabolic pathway (Figure 2). These are 
the genes for enzyme of biosynthesis of acetylcholine (Ach): 
choline acetyl transferase (CholAT), vesicular Ach transporter 
(VACHT), enzyme of Ach degradation acetylcholine esterase 
(AchE), receptors (muscarinic, M1-M5 and nicotinic, N), G 
proteins (pertussis toxine sensitive inhibitory G protein Gi and 
pertussis toxine insensitive G protein Gq), enzymes of intracellular 
signal transduction (adenyl cyclase- AC, guanylil cyclase- GC, 
protein lipase Cβ (PLCβ), protein kinase C (PKC), key enzyme in 
endothelium dependent vascular smooth muscle relaxation nitric 
oxide synthase (NOS), and ion channels, with special emphasis on 
Ca2+ and K+ channels.
Vasovagal syncope
Vasovagal syncope (VVS, reflex syncope, neuraly mediated syncope, 
neurocardiogenic syncope, emotional fainting) is a common 
clinical problem, characterized by transient episodes of loss of 
consciousness due to abnormal autonomic activity [111,116,117]. 
Classical VVS is mediated by emotional, and/or orthostatic stress. 
It is diagnosed when precipitating events such as fear, severe 
pain, emotional distress or prolonged standing are associated 
with typical prodromal symptoms [118]. Pathophysiology of VVS 
is still unclear [116,118-122]. According to the polyvagal theory, 
the neural regulation of the autonomic nervous system passes 
through three global stages, each with associated behavioral 
strategy [123]. In mammals a dorsal vagal complex, the vestigial 
immobilization system, has a role in generation of VVS, as a typical 
behavioral response to environmental challenges. This theory 
puts the light on the possible pathophysiological mechanisms of 
centrally (emotionally) induced VVS, while the VVS induced by 
orthostatic stress has a variety of proposed pathophysiological 
mechanisms, where vagal system again plays pivotal role [116]. 
Hereditary aspects of VVS were studied in 19 studies so far [124]. 
Clinical descriptions of familial VVS are scarce and determined a 
positive family history in 19-90% of the VVS patients [125-127]. 
Association studies of neurohumoral candidate 
genes and VVS
Few studies examined potential genetic polymorphisms associated 
with VVS and, due to still unrevealed pathophysiological process, 
were focused on different neurohumoral systems that participate 
in the regulation of circulatory homeostasis. 
Newton et al., examined the influence of ACE insertion/deletion 
(I/D) polymorphism, which could lead to altered circulating 
angiotensin levels, finding that there was no significant difference 
in distribution of ACE I/D gene frequencies in 165 cases compared 
with a large national control population [128]. The endothelin 
system was also investigated for the role of endothelin-1 genetic 
polymorphisms in VVS, and its association with vasodepressive 
form of VVS was found [129].
The functional role of ADRB1 polymorphism Arg389Gly on 
susceptibility to develop a positive head up tilt test (HUT) was 
suggested [130]. Subjects with Gly389 have lower cardiac 
inotropic response to catecholamines and this could therefore 
dysregulate the autonomic respose to HUT [130]. Marquez et al., 
[117] studied this polymorphism in 50 patients with unexplained 
syncope. The Gly389 allele was more frequently present in VVS 
patients with positive HUT test than in HUT negative subjects [117]. 
Hernandes-Pacheco et al., [131] also investigated the correlation 
between VVS and ADRB1 polymorphism at the 389 position. 
Their results suggest that the VVS has a genetic component 
associated with Arg389Gly polymorphism of ADRB1. Sorrentino 
et al., considered eight polymorphisms influencing sympathetic 
activity as a major risk factor for VVS in Italian patients [132]. They 
analysed polymorphisms of ADRA1A, ADRB1, ADRB2, GNB3, DBH 
and SLC6A4 gene. No association of the aforementioned genetic 
variants with both HUT outcomes and new syncopal episodes 
during follow-up was found [132]. Considering the small number 
of patients that were enrolled in these studies, further studies 
are needed to correlate haemodynamic resposes to autonomic 
tests with polymorphic variations in genes. Even though some 
data speak for the role of ADRB1 in susceptibility to VVS [117], 
there is an increasing evidence that genetic polymorphisms 
of sympathetic signaling pathway are not associated with tilt-
induced VVS [128]. This brought the authors to the conclusion 
that an emphasis should be put on the parasympathetic genes 
and their interaction with the environment. 
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Studies of candidate genes of acetylcholine homeostasis: 
biosynthesis (CholAT), vesicular packing (VACHT), enzyme 
degradation (AchE) and choline uptake from synaptic cleft (ChT) 
in VVS
Even though there is a considerable amount of the literature that 
speaks for the role of CholAT in Alzheimer disease [133], bipolar 
disorder [133,134] and schizophrenia [135] to our knowledge no 
study was done on the role of its genetic polymorphisms in VVS. 
Due to the key role of Ach in locomotion it was very complex 
to study on animal models the role of genetic disturbance in 
cholinergic neurotransmission of autonomic nervous system and 
consequently on cardiovascular system [136,137]. Recently, a 
mutant animals for different components of cholnergic signaling 
pathway have been developed [138], which opened the trace of 
studying the role of cholinergic genes in initiation and, interestingly, 
the withdrawal of the pathophysiological process of different 
diseases of autonomic nervous system[139]. The cardiovascular 
parameters (heart rate and arterial blood pressure) important 
for the pathophysiological process of VVS, were not altered in 
VACHT mutant mice, while the sympathetic predominance on 
the heart level was observed. Still, an important caveats for these 
results are that the measuring of the cardiovascular parameters 
was performed under the halothane anesthesia, which can 
independently alter neural regulation of cardiocerebrovascular 
system [140,141]. The essential result on molecular genetics 
level of this complex and interesting study is the evidence that 
the insufficiency of acetylcholinergic neurotransmission in VACHT 
mutant mice induce the cascade of genetic expression alterations 
of the vast number of proteins participating in autonomic nervous 
system regulation: M1, M2 and M3 receptors, ADRB1, GRK2 and 
GRK5. This is in line with the increasing evidence that some 
neurocardiovascular diseases like HF [142,143] and VVS [111]are 
the result of complex interactive dysfunction of both sympathetic 
and parasympathetic branch of autonomic nervous system that 
occurs on systemic and molecular level [6,13]. The role of VACHT 
was investigated in different addictive behavior [144], locomotion 
[145] and cognition [146], and it’s role in autonomic dysfunctions 
was also observed: in HF [137], hypertension and cerebrovascular 
disease [147]. The fact that VVS is a behavioral phenomenon 
with emphasized autonomic phenomenology speaks indirectly 
in favor for the possible role of VACHT in VVS pathophysiology, 
and plausibly to it’s genetic background. AchE was found to be an 
important factor of the VVS and its cardioinhibitory component 
[148], taking into account vagal pathophysiology interacting with 
vasodepressor mechanisms. A cholinergic disfunction on the level 
of CholAT, VACHT and ChT gene transcription were described for 
the central cholinergic dysfunction in Huntington disease [149], 
but due to the inaccessibility of peripheral vagal fibers as well 
as to the fact that animal models of VVS are still developing 
[137,150], this issue is still not assessed in VVS. More, though 
there is prevailing opinion that VVS is the pathophysiological entity 
where multiple gene-gene and gene-environment interaction 
should be taken in the consideration [129], there is still a lack of 
data that include the parasympathetic genes in this network. In 
line with this hypothesis, recent data propose an animal model 
of vagal hyperactivity [137], assessed by relatively noninvasive 
technique of heart period time domain analysis [6], suggesting 
that inheritance model of vagal hyperactivity could correspond 
to polygenetic model with the partial sex-limited character. New 
investigations in the area of genetic studies are needed for the 
confirmation of these hypotheses on the role of Ach homeostasis 
gene in VVS.
Studies of muscarinic receptor candidate genes 
and VVS
An interesting association was found between Alzheimer diseases 
(pathology with central Ach dysfunction) and VVS (pathology 
with peripheral acetylcholine dysfunction), with the crucial role 
of muscarinic receptors (M1) [151]. Central muscarinic receptors 
play an important role in different cardiovascular reflexes, like 
Bezold-Jarish reflex and baroreflexes [151].Thus, the alterations 
in central M1 activity can cause the autonomic dysfunction of 
cardiovascular system and makes it an interesting gene-candidate 
for the association of different gene polymorphisms and the 
incidence of VVS. The positive effect of ipratropiumbromide in the 
therapy of central VVS points out that the muscarinic receptors 
play an important role in the pathophysiology of VVS [152].
Novel data on the genetic overexpression of M2 and M3 receptors 
in the states of vagal hyperactivity, as it is the case of VVS, suggest 
that the existence of SNPs of these receptors (83% of vagally 
hyperactive animals) has an important role in the genesis of 
this pathophysiological state [153]. A compensatory increase of 
AchE gene expression in the same animal model of VVS speaks 
for the important gene-gene interaction in the acetylcholinergic 
signaling pathway. The association studies of SNPs of muscarinic 
receptors and VVS are lacking, but the growing corpus of genetical 
investigation on the role of muscarinic receptors in VVS will open 
the way for these investigations.
Association studies of G-proteins candidate 
genes and VVS
Lelonek et al., studied 217 VVS patients free from any other 
disease that were examined related to HUT results and genotyped 
for polymorphism in GNAS1 gene (polymorphism C393T), GNB3 
(polymorphism C825T) and for the cardiac regulator of G-protein 
signaling RGS2 (polymorphism C1114G) [154]. In multivariate 
logistic regression analysis, the homozygotes 825TT GNB3 (OR 
0.37; 95% CI 0.14-0.97; P < 0.05) and body mass index (OR 0.87; 
95% CI 0.78-0.97; P = 0.005) were independently associated 
with a lower chance of positive tilting results. The same 
authors studied in 68 positive tilted patients the GNB3 C825T 
polymorphism, which was associated with increased G protein-
mediated signal transduction [155]. On the basis of their results, 
the predisposition to VVS seems not to be associated with the 
GNB3 C825T polymorphism. The frequency of GNB3 825T allele 
was significantly higher in patients with non-typical VVS history 
than in group with typical history. Lelonek et al., investigated 
the relationship between GNAS1, GNB3 and the RGS2 with 
Calgary syncope syndrome score as the potential biomarkers 
for screening test for VVS [156]. Their results showed that 393T 
GNAS1 remained independent factor associated with positive 
tilt results. The authors suggested the variation of GNAS protein 
gene as a helpful test for identifying tilt-induced VVS patients.
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Although neurogenetic influences on the occurrence of VVS 
episodes seem possible, specific high risk polymorphisms have 
not been identified so far. Differences in vasovagal responses 
between the subjects and different mechanisms for the 
development of VVS suggest that various genetic polymorphisms 
could be of significance. 
Studies of other intracellular molecular signaling 
pathway genes and VVS
Increased concentration of plasma cAMP, implying on activity 
of AC has a role in pathophysiological process of VVS [157]. The 
authors link this result to the increased activity of sympathetic 
nervous system preceding the syncope event, though the 
contribution of parasympathetic signaling route cannot be 
excluded. To the best of our knowledge no investigation on the 
role of AC genetic polymorphisms in VVS has been done.
Calcium is one of the most important intracellular signaling 
particles in the parasympathetic signaling pathway. Dysfunction 
of calcium homeostasis is recognized to play an important role 
in many cerebrovascular and neurodegenerative diseases. 
Abnormalities of voltage gated calcium channels, the most 
important regulators of intracellular calcium concentration 
participate in vast number of human diseases, like migraine and 
episodic ataxia [158]. As parasympathetic activity plays a certain 
role in generation of these diseases[159], it is reasonable to 
hypothesize that genetic modulation of voltage gated calcium 
channels could play a role in pathophysiological process of VVS. 
So far, no studies were performed on the role of voltage gated 
Ca2+ channels genetic polymorphisms in VVS.
Adenosine, an ubiquitous purinergic nucleoside present in all 
living cells, participates in vast number of physiological processes-
regulation of vascular smooth muscle tone, heart rate and 
neurotransmission. It’s characteristic that, when administered 
exogenously, provokes negative chronotropic and dromotropic 
effects, was proved useful as a provocative test for VVS [160]. 
The mechanisms of it’s syncopogenic actions are still unexplained 
[161]. An interesting point is that the purinergic receptors 
on myocardial cells share common signaling output with 
muscarinic receptors-opening the potassium channels (Figure 
3) [162], implying that both physiological regulator systems of 
cardiomyocyte excitability, purinergic and cholinergic, could have 
the common bottleneck in VVS - the K+ channels. Differently 
from well known K+ channelopathies like long QT syndrome 
[163] and short QT syndrome [164], there are no data about the 
role of genetically modulated K+ channels in the pathogenesis of 
VVS. Coming back to the role of adenosine in VVS, the data on 
potential role of the genetic modulation of protein components 
of adenosine numerous biosynthetic pathways and the pathways 
of degradation [165] is still lacking.
2b. Candidate genes in vagally mediated atrial 
fibrillation
Atrial fibrillation (AF) affects more than 5 million people 
worldwide, making a prevalence of 1% in the general population. 
It is characterized by rapid, erratic electrical activation of the 
atrial myocardium, resulting in the loss of effective contractility, 
an increased likelihood of clot formation, and an increased risk 
of stroke. AF is presented as familial and non familial form [166].
Some studies investigating a molecular pathogenesis of AF have 
focused on familial forms of the disease. Recently, a mutation in 
KCNQ1, a K+ channel gene also implicated in a form of the long-
QT syndrome, was identified as the molecular basis of autosomal 
dominant AF in a single family from China [167]. Two additional 
families with autosomal dominant AF have been identified 
and the loci mapped to 10q22–q24 and 6p14–p16 [168,169]. 
However, a causal gene has not been identified. Familial forms 
of AF may provide insight into the molecular pathways involved 
in these selective cases of the disease, but the genetic defects 
identified may not be representative of the pathogenesis in the 
more common, nonfamilial form of AF. 
Differently from monogenic forms, caused by rare genetic 
mutations with high penetrance, the more present form of AF 
is likely to be caused by common genetic polymorphisms that 
arrhythmogenically interact with environmental factors [170]. A 
vast number of different gene polymorphisms were investigated 
and, interestingly, a morphological remodeling of different 
proteins due to genetic modulation gave the same AF form 
as did electrophysiologically remodeled proteins in different 
patophysiological conditions accompanied by AF. This speaks 
in favor of the common underlying mechanisms, that are still 
insufficiently revealed [171], with fact that different mechanisms 
operate in different circumstances [172].
Being the focus of this review, we will consider the balance 
between sympathetic and vagal influences as an important 
predictor of AF. Vagal predominance has been observed in the 
minutes preceding the onset of AF in patients with idiopathic 
paroxysmal AF, while in patients with organic heart diseases 
there is a shift toward sympathetic predominance [173]. In 
general, vagally mediated AF occurs at night or after meals 
[174], while adrenergically induced AF typically occurs during 
the daytime. In patients with vagally mediated AF, the more 
common form, adrenergic blocking drugs or digitalis sometimes 
worsen symptoms [175]. Some results suggest that simultaneous 
sympathovagal discharge is profibrillatory [176-178]. These 
conflicting results suggest that the complex interaction between 
autonomic nervous system and AF is due to individual variability, 
with some patients having more emphasized autonomic triggers 
than others [179].
Studies of candidate genes of acetylcholine homeostasis: 
biosynthesis (CholAT), vesicular packing (VACHT), enzyme 
degradation (AchE) and choline uptake from synaptic cleft (ChT) 
in vagally mediated atrial fibrillation 
Cholinergic neurons, both central and peripheral, express 
three proteins-CholAT, VACHT and ChT, that are in physiological 
equilibrium and in the function of the maintenance of 
physiological levels of Ach. The interrelation of the genes of 
these proteins and their polymorphic variances was investigated 
in syndromes like congenital myasthenic syndrome with episodic 
apnea [180] and genetically modulated animal models of central 
cholinergic dysfunction [181]. Even though it is intuitive that the 
gain-of-function genetic modulations influencing the quantity 
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and the release of Ach in neural-cardiomyocite synaptic cleft 
is of interest for pathophysiology of vagally mediated AF, no 
association studies have been performed in this direction.
Studies of muscarinic receptor candidate genes 
and vagally mediated AF
Increase of Ach release to neural-myocardiocyte synaptic 
cleft increases cardiac vulnerability to AF by muscarinic 
receptor-mediated shortening of refractory period. Different 
antiarrhythmic drugs perform their action by inhibiting 
muscarinic Ach receptors, but also by inhibiting the G proteins, 
the transduction proteins of cholinergic signaling pathway, and, 
finally, directly acting on K+ channels [182]. This fact makes these 
proteins an important candidate for genetic evaluation to vagally 
induced AF susceptibility.
The importance of muscarinic receptors in age dependent 
increase for AF susceptibility is strengthened by the fact that the 
expression of M2 in atrial cells is region dependent [183] and 
increases with age [184].
The data from the studies of systemic interrelations of sympathetic 
and parasympathetic system [185] speak for the importance of 
the adequate dynamic interrelation of these systems in different 
physiological states where cardiac autonomic regulation is 
under specific strain, like sleep [11,141,185] or positional and 
pharmacologic modulation of autonomic nervous system [186]. 
Having on mind that muscarinic receptors play an important role 
both for the downward transmission of cholinergic signal as well 
as for inhibition of adrenergic signaling [187,188] (Figure 2) it is 
probable that its functional modulation due to genetic variability 
might be of importance for initiation of different arrhythmogenic 
episodes, AF being one of them.
Association studies of G-proteins candidate 
genes and vagally induced AF
G proteins, the cellular transduction proteins, are of particular 
interest in the pathophysiology of AF. G proteins can couple 
both with M2 and ADRB2 receptors and mediate in this way the 
opposing effects of parasympathetic and sympathetic nervous 
system on the Ca2+ and K+ ion currents and cardiomyocite 
excitability [189]. The polymorphisms of GNB3 (C825T 
substitution), initially identified as a risk factor for hypertension 
[190] was targeted for its association with atrial fibrillation [191]. 
Although previously identified as a cardiovascular risk factor, in 
the case of atrial fibrillation TT genotype manifested protective 
effect.
Magnitude and duration of G protein coupled receptor responses 
are regulated by the activity of the RGS family of proteins [189]. 
These proteins act as GTPase stimulating proteins of GNAS1. 
Many of these proteins are detectable in sinoatrial node, 
atrioventricular node, atrial and ventricular cells and perform 
there their modulating action on cellular electrophysiology. Two 
RGS proteins, RGS6 and RGS4, are found to be critical regulators 
of M2 transmission, functioning as the brake on vagal activity. 
Since there are results on the role of RGS proteins in AF in knock 
out animals [192], it is intuitive to conclude that the genetic 
polymorphisms of RGS proteins in the sence loss-of –function 
might be of importance in the pathophysiology of AF. Even though 
the research on the role of RGS polymorphisms in VVS [155] and 
hypertension [193,194] has been done, no studies on their role in 
AF has been performed.
Studies of other intracellular molecular signaling 
pathway genes and vagally induced AF
Even though ion handling molecules in AF can be observed 
independently, they make an integral, conclusive part of the 
neural signaling pathway to cardiomyocite [195-197]. In order 
to follow the scope of this review, we put an emphasis only on 
the most important findings in the genetic research of these 
molecules that participate in neural signaling dysfunction. For 
more detailed review on the ion handling molecules in AF the 
paper of Mahida and collaborates should be addressed [198].
Delayed afterdepolarizations are one of the basic mechanisms of 
AF generation, which results from altered intracellular homeostasis 
of Ca2+ [170] (Figure 2). The principal Ca2+ handling molecules 
are voltage-dependent Ca2+ channels, ryanodine receptors on 
sarcoplasmatic reticulum (RRS), the sarcoplasmatic Ca2+ ATPase 
(SERCA) and the cell membrane Na+, Ca2+-exchanger [199].
A feed-forward relation between AF and gene expression of 
above listed Ca2+ handling molecules was observed [195-199]. 
Additionally, the association was found between the large genomic 
deletion in RRS gene and different arrhythmic heart diseases that 
include AF [200]. A heterozygous missense mutation in RRS gene 
is also associated with different arrhythmic heart disease [201]. 
A role of RRS gene mutation in the AF genesis was confirmed in 
animal models, too [202].
The first link between ion channelopathies and AF was provided 
by Chen and collaborates [167]. The KCNQ1 gene encodes a 
pore-forming alpha subunit which associates with beta subunits, 
forming a delayed-rectifier K+ current which is prominent at 
higher heart rates and adrenergic stimulation during the late 
phase of the action potential. This mutation causes a marked 
slowing of K+ channel deactivation. A missense polymorphism in 
the minK gene is found to be associated with AF in patients from 
Taiwan population [203].
The one of genetic backgounds of AF was a loss-of-function SNP 
in KCNE1 which encodes the slow delayed-rectifyer K+ channel 
beta-subunit mink [204].
The mutation of KCNA5 that disrupts the structure and the 
function of Kv.1.5 conferees the susceptibility to action potential 
prolongation and the generation of AF [205]. A SNP of the KCNN3 
gene encodes dysfunctional Ca2+ activated K+ channel and is 
associated with AF [206].
Experimental data demonstrated that NO is involved in cardiac 
vagal activity, the inhibition of sympathetic activity, and the 
atrial electrophysiological remodeling [207], suggesting the 
potential pathophysiological route from vagal activity down to 
the heart electrophysiological remodeling. The authors evaluated 
the role of eNOS -786T>C, 894G>T, 4a/4b and of minK S38G 
polymorphisms as predisposing factors to non-valvular AF. The 
minK 38G allele was significantly associated with susceptibility 
to non-valvular AF. The eNOS -786C allele weakly influenced 
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non-valvular atrial fibrillation, according to the dominant model 
(OR=1.50, P=0.01). These findings suggest a role for minK and 
eNOS genes as predisposing factors to non-valvular AF.
These data speak in favor of the fundamental role of genes coding 
proteins of Ca2+ and K+ homeostasis in cardiac arrhythmogenesis, 
but also imply that the change at the functional level of these 
genes influences arrhythmogenic potential of the whole heart, 
where vagally induced AF represents only a segment of the 
complex picture of cardiac arrhythmias. 
Conclusions
The scope of this review was to present the state of the art on the 
role of candidate gene polymorphisms in signaling chain of neural 
transmission and metabolism in neurocardiovascular diseases, 
enlightening the missing links of data on this issue. 
In these multifactorial and prevalently multigenic diseases 
emphasize is put on the impact of neural (dys)regulation on the 
global pathophysiological situation. This impact is sometimes 
etiological factor and sometimes precipitating factor for 
aggravation of symptoms, in the worse case the fatal outcome 
[13]. From proteo-genetic point of view a vast number of 
molecules all along the neural signaling and metabolic pathways 
can be functionally modified and consequently be the background 
of the predisposition to the disease, its faster progression or its 
complicated form. Consequently, the identification of these genes 
makes an excellent diagnostic tool in the sense of right-time and 
right-choice therapy. The thorough evaluation of the impact of 
genetically modulated classical molecules in neurocardiovascular 
communication is still missing, while on the other hand there 
is an increasing knowledge on new molecules with modulatory 
effect on these systems. 
Special emphasis should be put on the fact that the impact of 
neural dysfunction on autonomic nervous system diseases of 
CV system is rarely the consequence of isolated dysfunction of 
parasympathetic or sympathetic nervous system, but more of 
the disequilibrium in joined modulation and dynamics of these 
two systems: this is the case for HF [142,143], AF [176-178] and 
VVS [13,6]. That is why, for the future neurogenetic research, 
an emphasis should be put on signaling molecules that provide 
the cross-talk between these two systems: on intercellular level 
(i.e. muscarinic receptors), on intracellular level (G proteins and 
molecular machinery that regulates their activity), or on the 
level of the integration of signaling process, like Ca2+ handling 
molecules or K+ channels. This also speaks strongly for the 
future necessity of redefining pathophysiological syndromes and 
didactic classifications of CV dysautonomias.
The vast palette of data obtained from association studies 
between SNPs of autonomic nervous system and different 
pathophysiological entities picture the genetic plasticity of 
neurocardiovascular signaling pathways. Different external 
or internal factors could act on genetic structure and trace 
different functional pathways of the same neurocardiovascular 
phenotype/disease [66,86,97]. This is typically the case of 
essential hypertension.
Additionally, an aggregation of positive results for the associations 
between certain genes and different pathophysiological 
phenotypes could be observed, pointing on the specific 
"neurocardiovascular genetic hotspots", obviously the genes 
with high pleiotropy. This is the case for: ADRB2 polymorphism 
association with hypertension [63], HF [48,49], SCD [208] 
and CAD [209], and G protein molecular machinery- GNAS1 
association with hypertension [76], HF [210] and VVS [156] and 
RGS association with VVS [155] and hypertension [193,194]. 
Having on mind that many neurocardiovascular diseases occur in 
clusters [210] identification of these genes could be of particular 
interest as a diagnostic tool in complex forms of these diseases.
The opening gate of GWAS studies will offer an insight into 
new candidate genes and new potential pathophysiological 
pathways that might elucidate better the neural role in the 
pathophysiological process of the neurocardiovascular disease. 
An important interpretational gaps that exists between the level 
of gene functioning, the cellular level of electrophysiological 
functioning and, finally, systemic physiological and the behavioral 
level of functioning of the organism, should be overcome by 
combined genetic, in vitro and in vivo studies of autonomic traits 
[211]. Additionally, due to the feed forward modulating effect 
of the pathophysiological process on the gene level, it is usually 
difficult to establish cause-effect relation [212]. Consequently, 
the creative unification of the insight from the systemic level of 
the disease (clinically-the stage of the disease) with the insight 
of data obtained by modern genetic techniques will trace the 
way for new interpretations of the interaction between genes 
and pathophysiological process in neurocardiovascular diseases. 
Syndomes like POTS, CPVT or cardiac dysautonomia in PD are 
indicative “intermediate phenotypes” that can offer both to the 
researchers a novel aspects on genetic background of ANS diseases 
and to clinicians a valuable landmark for disease progression. Role 
of the molecules of parasympathetic homeostasis [204-207] in 
genesis and regression of certain neurocardiovascular disorders 
is on the very beginning of the promising future SNPs and GWAS 
studies.
Drugs that interfere with autonomic control of the heart and 
vasculature that are used in the treatment of arrhythmias, 
hypertension, and HF are still not able to cure the diseases [6]. 
New data obtained from neurogenetic approach will improve 
the disease outcome by pharmacologic, gene and behavioral 
modulationof the autonomic nervous system [66,213,214].
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